Summit Therapeutics plc (‘Summit’ or the ’Company’)
Summit Therapeutics to Participate in Upcoming Investor Events
Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two upcoming investor events.
- BIO Investor Forum, Mr Glyn Edwards is speaking on the panel “Using Microbiome-Based Therapies to Improve Patient Outcomes,” 10:45am PDT, 17 October 2018 in San Francisco, CA
- BTIG Biotech Conference, 25 October 2018 in New York City
At these events, management will conduct one-on-one meetings; there will be no podium presentations.
About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
|Glyn Edwards / Richard Pye (UK office)||Tel:||44 (0)1235 443 951|
|Erik Ostrowski / Michelle Avery (US office)||+1 617 225 4455|
|Cairn Financial Advisers LLP (Nominated Adviser)||Tel:||+44 (0)20 7213 0880|
|Liam Murray / Tony Rawlinson|
|N+1 Singer (Joint Broker)||Tel:||+44 (0)20 7496 3000|
|Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking|
|Panmure Gordon (Joint Broker)||Tel:||+44 (0)20 7886 2500|
|Freddy Crossley, Corporate Finance James Stearns, Corporate Broking|
|MSL Group (US)||Tel:||+1 781 684 6557|
|Jon Siegal||[email protected]|
|Consilium Strategic Communications (UK)||Tel:||+44 (0)20 3709 5700|
|Mary-Jane Elliott / Jessica Hodgson /||[email protected]|